18Feb 2017

A STUDY OF DIFFERENT PHENOTYPIC PRESENTATIONS OF POLYCYSTIC OVARIAN SYNDROME: AN INSTITUTIONAL EXPERIENCE

  • Assistant professor, Department of Obstetrics and Gynecology, S.S.Institute of Medical Sciences and Research Centre, Davangere, Karnataka, India.
Crossref Cited-by Linking logo
  • Abstract
  • Keywords
  • References
  • Cite This Article as
  • Corresponding Author

Background:Polycystic ovarian syndrome(PCOS) constitutes one of the most common endocrinopathy amongst the reproductive age women.Over the last few decades it has gained a lot of public attention as reflected in various internet sites and newspapers. However, it is a very complex endocrinopathy presenting as a challenge to clinician to make diagnosis and manage appropriately. Aims: To study the different clinical presentations among women with PCOS and to categorise them into different phenotypes. Method: An explorative hospital based study was conducted including 120 women with PCOS, during a two year period between Dec.2014 to Dec.2016. Based on history, clinical examination, hormonal evaluation and ultrasound features, all women were categorized into 4 different phenotypes. Results: Out of 120 women, 29(24.16%)presented with full blown syndrome(severe PCOS), 34(28.33%) had oligo/anovulatory PCOS, 25(20.83%) of them were found to be ovulatory variety and 32(31.17%) belonged to mild PCOS category. Conclusion:PCOS is represents a continuum of symptoms. No single test or clinical feature is sine qua non of the syndrome. This study demonstrates the various phenotypic expressions of PCOS and it can be viewed as a lifelong disorder with progession from mild to severe variety later on in life. Approach to each patient should be tailor made.


  1. Azziz R CE, Dewailly D, Diamanti-KandarakisE,Escobar-Morreale HF, Futterweit W, Janssen OE, Legro RS, Norman RJ, Taylor AE, Witchel SF: Task Force on the Phenotype of the Polycystic Ovary Syndrome of the Androgen Excess and PCOS Society. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. FertilSteril 2009;91:456.
  2. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004;19:41.
  3. Cussons AJ, Bronwyn GA, Stuckey G, Walsh JP, Burke V,Norman RJ: Polycystic ovarian syndrome: marked differences between endocrinologists and gynecologists in diagnosis and management. ClinEndocrinol 2005;62:289.
  4. Balen AH, Laven JS, Tan SL, Dewailly D: Ultrasound assessment of the polycystic ovary: international consensus definitions. Hum Reprod Update 2003;9:505?514.
  5. Broekmans FJ, Knauff EA, Valkenburg O, Laven JS, Eijkemans MJ, Fauser BC: PCOS according to the Rotterdam consensus criteria: change in prevalence among WHO-II anovulation and association with metabolic factors. Br J ObstetGynecol 2006;113:1210.
  6. Ibanez L, de Zegher F, Potau N: Anovulation after precocious pubarche: early markers and time course in adolescence. J ClinEndocrinolMetab 1999;84:2691.
  7. Shaw LJ, BaireyMerz CN, Azziz R, Stanczyk FZ, Sopko G, Braunstein GD, Kelsey SF, Kip KE, Cooper-Dehoff RM, Johnson BD, et al: Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the National Institutes of Health ?National Heart, Lung, and Blood Institute sponsored Women?s Ischemia Syndrome Evaluation. J ClinEndocrinolMetab 2008;93:1276.
  8. Vermeulen A, Verdonck L, Kaufman JM: A critical evaluation of simple methods for the estimation of free testosterone in serum. J ClinEndocrinolMetab 1999;84:3666
  9. Diamanti-KandarakisE, Panidis D: Unravelling thephenotypic map of polycystic ovary syndrome(PCOS): a prospective study of 634 women withPCOS. ClinEndocrinol (Oxf) 2007;67:735.
  10. Moran L, Teede H: Metabolic features of the reproductivephenotypes of polycystic ovary syndrome.HumReprod Update 2009;15:477.
  11. Diamanti-Kandarakis E, Christakou C, Palioura E, Kandaraki E, Livadas S: Does polycystic ovary syndrome start in childhood? PediatrEndocrinol Rev 2008;5:904.
  12. Yildiz BO, Bolour S, Woods A, Moore A, Azziz R: Visually scoring hirsutism. Hum Repr Update 2010; 16:51.
  13. Dilbaz B, Ozkaya E, Cinar M, Cakir E, Dilbaz S: Cardiovascular disease risk characteristics of the main polycystic ovary syndrome phenotypes.Endocrine 2011;39:272.
  14. Amato MC, Verghi M, Galluzzo A, Giordano C:Theoligomenorrhoic phenotypes of polycystic ovary syndrome are characterized by a high visceral adiposity index: a likely condition of cardiometabolic risk. Hum Reprod 2011;26:1486.

[Malavi ka J.C. (2017); A STUDY OF DIFFERENT PHENOTYPIC PRESENTATIONS OF POLYCYSTIC OVARIAN SYNDROME: AN INSTITUTIONAL EXPERIENCE Int. J. of Adv. Res. 5 (Feb). 291-296] (ISSN 2320-5407). www.journalijar.com


DR J.C. MALAVIKA
S.S. INSTITUTE OF MEDICAL SCIENCES

DOI:


Article DOI: 10.21474/IJAR01/3146      
DOI URL: http://dx.doi.org/10.21474/IJAR01/3146